Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Next-Generation Sequencing Identifies a Previously Uncharacterized Gene ANKRD36 As a Common Biomarker for Blast Crisis Chronic Myeloid Leukemia: Molecular and Protein Bio-Modeling Studies

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-143068

Published: 2020

Journal Articles

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Zafar Iqbal, BSc, MSc, PhD, Muhammad Absar, BSc, MSc, PhD, Abid Jameel, MD PhD, Tanveer Akhtar, PhD, Sulman Basit, PhDMSc, Aamer Mahmood, PhD, Aamir Aleem, MBBS FRCP, Nawaf Alanazi, MBBS FRCPC, Ullah Anhar, Naila Batool Khalid, Sibtain Afzal, Jamil Amjad Hashmi, Afia M Akram, PhD, Khushnooda Ramzan, PhD, Mahmood Rasool, Muhammad Hasaan Aziz, Muhammad Farooq Sabar, PhD, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid, PhD

Blood (2019) 134 (Supplement_1): 2939.

https://doi.org/10.1182/blood-2019-125518

Published: 2019

Journal Articles

BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses

Afia Muhammad Akram, PhD, Tanveer Akhtar, PhD, Asma Chaudhary, Muhammad Mudassar Shahzad, Ahmad Mukhtar Khalid, PhD, Nadia Sajid, MBBS, FCPS, Muhammad Farooq Sabar, PhD, Zafar Iqbal, BSc, MSc, PhD

Blood (2018) 132 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2018-99-111757

Published: 2018

Journal Articles

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

Zafar Iqbal, MPhil PhDPost-doc., Afia Muhammad Akram, Tanveer Akhtar, PhD, Aamer Aleem, MBBS FRCP, Muhammad Farooq Sabar, PhD, Zeba Aziz, MD MBBS, Nadia Sajid, Mahmood Rasool, PhD, Muhammad Asif, Mehmood Husssain Qazi, PhD, Saleh Oraibi, PhD, Ammara T Gill, MBBS ABIM, Khalid Al Jamaan, MDFRCPC, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid

Blood (2016) 128 (22): 3089.

https://doi.org/10.1182/blood.V128.22.3089.3089

Published: 2016

Journal Articles

High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings

Zafar Iqbal, PhD, Afia Muhammad Akram, Tanveer Akhtar, PhD, Muhammad Khalid, MPhil PhD, Zeba Aziz, MD MBBS, Aamer Aleem, MBBS FRCP, Ammara T Gill, MBBS ABIM, Ahmad M Khalid, PhD, Abdullah Alanazi, MBBS, Ijaz H Shah, MD, Muhammad Khalid, MBBS, MPhil, Muhammad Farooq Sabar, PhD, Mudassar Iqbal

Blood (2015) 126 (23): 5167.

https://doi.org/10.1182/blood.V126.23.5167.5167

Published: 2015

Journal Articles

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Blood (2014) 124 (21): 1810.

https://doi.org/10.1182/blood.V124.21.1810.1810

Published: 2014

NARROW

Next-Generation Sequencing Identifies a Previously Uncharacterized Gene ANKRD36 As a Common Biomarker for Blast Crisis Chronic Myeloid Leukemia: Molecular and Protein Bio-Modeling Studies

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Email alerts

ASH Publications

American Society of Hematology

Next-Generation Sequencing Identifies a Previously Uncharacterized Gene ANKRD36 As a Common Biomarker for Blast Crisis Chronic Myeloid Leukemia: Molecular and Protein Bio-Modeling Studies

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only